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ABSTRACT
Eugenol (EU) is a phenylpropene, an allyl chain-substituted guaiacol. EU is a member of the phenylpropanoids class of chemical compounds. It is a 
colorless to pale yellow oily liquid extracted from certain essential oils especially from clove oil. Further, chemopreventive agents might be used singly 
or in combination with chemotherapy or radiotherapy for the more effective treatment of cancer by enhancing the efficacy of these modalities with 
minimal side effects and toxicity. Considering that EU scaffold may be a prospective chemopreventive agent, its potent antitumor ability to interfere 
with solid cancer cell growth and its molecular mechanism were evaluated as an initiative toward the development of a novel strategy for cancer 
treatment. This review article will conduct that EU as the antiproliferative activity and molecular mechanism of the EU induced apoptosis against the 
cancer cells and animal models.
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 INTRODUCTION
Apoptosis is a key hallmark of cancer [1]. In general, cells can die by 
apoptosis, a form of programed cell death. The activation of proapoptotic 
factors, resistance to apoptosis is often due to upregulation of 
antiapoptotic factors. Thus, a number of genes that encode components 
of the apoptotic machinery are directly targeted by activating or 
inactivating genetic lesions in cancer cells. It is accompanied by 
various morphological changes such as nuclear condensation and 
fragmentation, isolation of cytoplasmic organelles into discrete regions, 
formation of surface membrane and fragmentation of the dead or 
dying cell into membrane-bound bodies [2]. The Bcl-2-protein family 
regulates cell death and proliferation [3,4], two processes dysregulated 
during oncogenic transformation. Thus, it is not surprising to find an 
upregulation of Bcl-2 expression in many cancers, including chronic 
lymphocytic leukemia Bcl-2 is highly expressed at the onset of many 
cancers [3-5]. In addition to B-cell lymphomas [6], Bcl-2 has been 
implicated in solid tumors [7] and non-small cell lung cancer [8]. 
The antiapoptotic Bcl-2-proteins are highly promising targets for the 
development of novel anticancer treatments.
To prevent such degenerative diseases, natural and synthetic drugs 
have gained significant attention. Used the synthetic drugs, natural 
phytochemical compounds and drugs based on monoclonal antibody. 
Chemically synthesized anticancer drugs have toxic side effects and 
usually cause potential damage to normal cells. Antitumor activity has 
been reported for essential oils against several tumor cell lines [9-11], 
and these oils contain a high percentage of phenylpropanoids. The 
phenylpropanoid pathway is responsible for the biogenesis of several 
structurally diverse groups of compounds. Many phenylpropanoids have 
the potential to act as antioxidants, modulate the activity of cytochrome 
P450 and the enzymes in the arachidonic acid cascade, activate phase 
II reactions and affect cell signaling. In vitro many have been shown 
to inhibit bacterial and viral replications [12]. This compounds with 
scaffold phenylpropanoids including Eugenol (EU), flavonoids, catechins, 
gingerol, coumarins, plant sterols, and phytoestrogens have a variety 
of therapeutic properties ranging from antibacterial and antiviral, 
and ability to protect against heart disease and various cancers [12]. 
The scaffold phenylpropanoids, which are believed to contribute to 
their pharmacological activity [13]. Phenylpropanoids scaffolds, such 
as thiosemicarbazones and coumarin, can inhibit topoisomerase II 
enzyme. The anticancer activities of thiosemicarbazones were closely 
related to the parent aldehyde or ketone group and terminal amino 
substitution [14]. Coumarin derivatives with compounds 3, 6-dibutyl-
7-hydroxy-4-oxo-2-chlrobenzyl -4H chromene -8- carbaldehyde are 
excellent promoters of N-acetyltransferase 2 inhibitor [15]. EU shows 
better application potential in the prevention and treatment of some 
cancers. The anticancer activity of EU has become an important 
research topic in recent years.
EU 1 and its derivatives have been reported to inhibit colon cancer cell 
proliferation by arresting the cells in sub G1 phase, augment reactive 
oxygen species (ROS) levels that result in DNA fragmentation, which 
is a hallmark of apoptosis. It has been reported that EU is a phenolic 
compound that induces apoptosis in human colon cancer cells [16]. The 
antiproliferative activity of EU against melanoma [17], leukemia [18], 
gastric [19], skin tumor [20], and prostate cancer [21] cells has been 
confirmed by many researchers. Structure of phenylprepanoids, eugenol 
scaffold and its derivatives as anticancer as Fig. 1. while the related 
research on phenylprepanoids, eugenol scaffold and its derivatives as 
anticancer as Table 1.
ANTICANCER ACTIVITY OF PHENYLPROPANOIDS, EU SCAFFOLD 
AND ITS DERIVATIVES
Activity of phenylpropanoids, EU scaffold and its derivatives 
against colon cancer
Colorectal cancer is the second most common malignancy in women 
and the third in men worldwide with an increasing incidence. In 
addition, colorectal cancer is the fourth common cause of death from 
cancer. Even if advances in drug development and surgery led to an 
increased overall survival, the prognosis of patients with metastasized 
colorectal cancer is still limited [22]. The treatment of colorectal cancer 
with EU resulted in reduction of intracellular non-protein thiols and 
increase in the earlier lipid layer break. Further events like dissipation 
of matrix metalloproteinases (MMP) and generation of ROS were 
accompanied in the EU induced apoptosis. ROS generation resulted in 
the DNA fragmentation of treated cells as shown by DNA fragmentation 
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and TUNEL assay. Further activation of p53 and caspase-3 was 
observed in Western blot analyses. The results demonstrated molecular 
mechanism of EU -induced apoptosis in human colon cancer cells. This 
research will further enhance EU as a potential chemopreventive agent 
against of colon cancer [16]. Another research was conducted that EU 
combine with canola oil showed an antiproliferative effect against colon 
cancer cell lines depending on the concentration and the cell lines used. 
Further EU with canola oil exhibited lower IC50 values against both cell 
lines compared to EU 1 both EU and EU with canola oil induced sub 
G1/S cell cycle arrest and apoptosis via ROS-dependent mechanism. 
Thus, results suggest that EU 1 and EU with canola oil have similar 
antiproliferative mechanisms against colon cell lines. Therefore, this 
research further enhances EU as a potential chemopreventive agent 
against colon cancer. In future, mechanism of intracellular induced ROS 
that triggers apoptosis will be considered [23]. Other study conducted 
with bi EU (magnolol) 2. This results of the study have shown that 
magnolol 2 downregulated expression of the antiapoptotic protein 
Bcl-2, upregulated expression of pro-apoptotic protein p53 and Bax, and 
caused the release of mitochondrial cytochrome c. Magnolol 2 induced 
p53 and Bcl-2 expression was abolished in the presence of magnolol 
compound. Magnolol inhibited migration and invasion of HCT-116 cells 
through AMPK activation [24]. These findings demonstrate that AMPK 
mediates the anticancer effects of magnolol through apoptosis in 
HCT-116 cells. Several researchers have shown that magnolol inhibits 
proliferation and induces apoptosis in cancer cells by inhibiting DNA 
synthesis [25], signaling pathway as well as Ras/Raf-1/Erk actions [26]. 
However, it remains to be determined whether apoptotic cell death is 
associated with the AMPK signaling pathway in HCT-116 colon cancer 
cells treated with magnolol.
Anticancer activity of phenylpropanoids, EU scaffold and its 
derivatives against breast
Breast cancer remains a worldwide public health concern and a major 
cause of morbidity and mortality among females [27]. Many studies 
have proved that EU 1 upregulated the versatile cyclin-dependent 
kinase inhibitor p21WAF1protein, and inhibited the proliferation of 
breast cancer cells in ap53-independent. These antiproliferative and 
pro-apoptotic effects were also observed in vivo in xenografted human 
breast tumors [28].
Faatma et al. [29] conducted that derivatives EU potent to inhibitory 
activity against MDA-MB-231 cell migration at the 1-4 lM dose range. 
The derivatives EU with Z isomers compound 3 and 4 were more active 
as invasion inhibitors compared to their structurally related E isomers 
5 and 6. The cytotoxic activities of compounds 3, 4 against two breast 
cancer cell lines MDA-MB-231 and human cancer cell-7 (MCF-7) were 
evaluated. Anti-invasive activity of the semisynthetic derivatives is 
not due to a direct cytotoxic effect on MDA-MB-231. Compound 3,4 
may promote their anti-invasive activity through the induction in cell 
morphology.
Another study observed that EU could suppress breast cancer cell 
migration which was mediated mainly through decreasing the MMP-9 
and paxillin gene expression. EU could inhibit cell proliferation and 
migration of MCF-7 cells dose and time dependently. On the other hand, 
EU-treated cells displayed condensed and fragmented nuclei compared 
to the control group [30]. Effect of EU on intracellular redox status of 
the human breast cancer cells was assessed by determining the level 
of glutathione and lipid peroxidation products. EU treatment inhibited 
the growth and proliferation of human MCF-7 breast cancer cells 
through induction of cell death, which was dose and time dependent. 
Microscopic examination of EU treated cells showed cell shrinkage and 
apoptotic body formation. Further, EU treatment also depleted the level 
of intracellular glutathione and increased the level of lipid peroxidation. 
The dose-dependent increase in the percentage of apoptotic cells and 
DNA fragments suggested that apoptosis was involved in EU-induced 
cell death and apoptosis have played a role in the chemopreventive 
action of EU [31].
Anticancer activity of phenylpropanoids, EU scaffold and its 
derivatives against cervical cell
Cervical cancer is caused by human papillomavirus infection. Most 
human papillomavirus infection is harmless and clears spontaneously, 
but persistent infection with high-risk human papillomavirus 
(especially type 16) can cause cancer of the cervix, vulva, vagina, 
anus, and oropharynx. The virus exclusively infects epithelium and 
produces new viral particles only in fully mature epithelial cells. 
Human papillomavirus disrupts normal cell-cycle control, promoting 
uncontrolled cell division, and the accumulation of genetic damage [32]. 
Hemaiswarya et al.’s [33] study of combination of phenylpropanoids 7 
with 5-fluorouracil as anticancer agents against human cervical cancer 
(HeLa) cell line. The study they observed that cytotoxic activity of 
phenylpropanoid scaffold was in the order of EU 1 >ferulic 8 >cinnamic 
9 >caffeic 10 >chlorogenic 11 >p-coumaric 12 >3,4-dimethoxycinnamic 
13 >2,4,5-trimethoxycinnamic acids 14. EU and ferulic, cinnamic and 
caffeic acids exhibited synergy with 5-fluorouracil. Synergy between 
compounds arises because of their different modes of action. There 
was a significant increase in the number of apoptotic cells in the 
combination when compared to the individual treatments. Treatment 
with a combination of 5-fluorouracil and EU increased the number 
of cells in the G0/G1 and G2/M phase when compared to control. 
An increase in cells in the sub-G1 phase was also observed. Another 
research conducted that EU showed dose-dependent selective 
cytotoxicity toward HeLa cells in comparison to normal cells, pointing 
to its safe cytotoxicity profile. A combination of EU and gemcitabine 
induced growth inhibition and apoptosis at lower concentrations, 
compared with the individual drugs. The analysis of the data using 
a combination index (CI) showed CI values of <1 indicating strong 
synergistic interaction. In addition, the expression analysis of genes 
involved in apoptosis and inflammation significant downregulation 
of Bcl-2, cyclooxygenase-2 (COX-2), and Interleukin-1β (IL)-1β on 
treatment with EU. The results suggest that EU exerts its anticancer 
activities via apoptosis induction and anti-inflammatory properties 
and provide demonstrated synergic between EU and gemcitabine, 
which enhance the therapeutic index of prevention and/or treatment 
of cervical cancer [34].
Several research studies to treatment combinations sulforaphane and 
EU induces differential effects on human cervical cancer cells. Treatment 
EU and sulforaphane with variable dose resulted in differential effects 
with an antagonistic effect at lower and synergistic at higher sub-
lethal doses as reflected in cell cytotoxicity and apoptosis induction. 
Importantly, gemcitabine used in conjunction with the low- and 
high-dose combinations showed no significant cell death at lower 
doses suggesting that cell cytotoxicity is proportional to gemcitabine 
alone, whereas at higher sub-lethal doses of sulforaphane and EU, 
it was found to act in a synergistic with gemcitabine. Furthermore, 
sulforaphane and EU combinations at synergistic dose significantly 
downregulated the expression of Bcl-2, COX-2, and IL-β but not the 
antagonistic combinations [35]. Another study was conducted of effect 
hydroxychavicol 17 and its analogs 18 with significant anti-proliferative 
activity in the micromolar range in HeLa cell line. From the 15 novel 
hydroxychavicol analogs with varying anti-proliferative activities in 
cervical cancer cell lines that show very encouraging results compared 
to the parent compounds [36].
Anticancer activity of phenylpropanoids, EU scaffold and its 
derivatives against melanoma
Malignant melanoma arises from the malignant transformation 
of epidermal melanocytes due to both environmental and genetic 
factors [37]. Melanoma is the most rapidly increasing malignancy in 
the white population [38]. Arung et al., 2011, were observed that EU 
and EU acetate 19 were isolated as the active compounds showed 
melanin inhibition of 60% and 40% in B16 melanoma cell with less 
cytotoxicity at the concentration of 100 and 200 μg/mL, respectively. 
Furthermore, an essential oil prepared from the bud of clove, which 
contains EU and EU acetate as dominant components, showed melanin 
inhibition of 50% and 80% in B16 melanoma cells at the concentration 
43
Asian J Pharm Clin Res, Vol 10, Issue 3, 2017, 41-46
 Fadilah et al. 
Fig. 1:  Phenylpropanoids, eugenol scaffold and its derivatives as anticancer
of 100 and 200 μg/mL, respectively [39]. EU and iso EU monomers 
20 and their respective O,O’-dimethyl-dehydrodi EU 21 did not show 
to inhibit melanoma cells proliferation. Conversely, the dimeric forms 
(biphenyls) showed some antiproliferative activity which was mild for 
dehydrodi EU, higher for its O,O’-methylated 22 form (O,O’-dimethyl-
dehydrodieugenol), and markedly pronounced for the racemic mixture 
of the brominated biphenyl (6,6’-dibromo-dehydrodieugenol) (S7) 23, 
being its enantiomeric form (S) 24 the most effective compared to the 
other compounds. Such activity resulted to be selective against tumor 
cells, without affecting cultured normal human skin fibroblasts. Dose 
and time dependence curves have been obtained for the enantiomeric 
form S7-(S). Then, IC50 and minimal effective doses and times have 
been established for the melanoma cell lines tested. TUNEL and 
phosphatidylserine exposure assays demonstrated the occurrence 
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of apoptotic events associated with the antiproliferative activity of 
S7-(S). Cytotoxic activity and apoptosis induced by treating melanoma 
cells with EU -related biphenyls was partially dependent by caspase 
activation [40].
Another study conducted that deregulation of E2F1 may be a key factor 
in EU-mediated melanoma growth inhibition both in vitro and in vivo. 
Since the E2F transcription factors provide growth for the continuous 
proliferation of melanoma cells, these results suggest that EU could 
be developed as an E2F-targeted agent for melanoma treatment [17]. 
Examination of the mechanism of the anti-proliferative action of EU in 
the human malignant melanoma cell line, WM1205Lu, showed that it 
arrests cells in the S phase of the cell cycle. Flow cytometry coupled 
with biochemical analyses demonstrated that EU-induced apoptosis. 
The E2F proteins are a family of transcription factors with an important 
role in regulating cell cycle progression [41]. It has been shown that 
deregulated transcriptional activity of the E2F family in autonomously 
growing melanoma cells provides for continuous proliferation of 
melanoma cells. Specifically, E2F2 and E2F4 are predominant in 
actively proliferating melanocytes, melanoma cells, and freshly isolated 
melanoma tumors.
Anticancer activity of phenylpropanoids, EU scaffold and its 
derivatives against Leukemia
Leukemia is widely called blood cancer and it is characterized by 
uncontrolled growth of blood cells produced in the bone marrow. It 
has estimated that 6020 people (3,140 in males and 2,880 in females) 
will be affected and 1440 people will die of leukemia in 2014 [42]. 
Jaganathan et al., 2014, were evaluated of honey and one of its phenolic 
constituent EU against L1210 lymphoid leukemia. The EU treated 
with intraperitoneal injection to mice could not increase the median 
survival time (MST) of animals. Further, there was only slight marginal 
increase in the %T/C values of EU treated groups. This study limits 
the use of selected EU against leukemia animal model. Antitumor 
effect of EU against L1210 leukemia animal model, result showed the 
EU displayed nonsignificant anti-leukemic activity compared with 
the positive control. This result serves as an indicator that the higher 
phenolic content of EU may not be always a prime factor to promote 
antitumor effect in leukemia animal model. Further apoptotic activity 
of EU in certain leukemia cancer cell lines may not correlate with 
the anti-leukemic effect observed on L1210 animal model [18]. But 
in the other studied that EU treated HL-60 cells displayed features 
of apoptosis including DNA fragmentation and formation of DNA 
ladders in agarose gel electrophoresis. The study observed that EU 
transduced the apoptotic signal via ROS generation, thereby inducing 
mitochondrial permeability transition, reducing anti-apoptotic protein 
Bcl-2 level, inducing cytochrome c release to the cytosol and subsequent 
apoptotic cell death. This study demonstrated that ROS plays a critical 
role in EU induced apoptosis in HL-60, and this is the first report on the 
mechanism of the anticancer effect of EU [43].
Anticancer activity of phenylpropanoids, EU scaffold and its 
derivatives against gastric
Gastric cancer can progress through of multistep process from chronic 
gastritis frequently resulting from Helicobacter pylori infection to gastric 
atrophy, intestinal metaplasia, dysplasia, and finally to carcinoma [44]. 
Although different genetic and epigenetic alteration involving oncogenes 
activation, tumor suppressor genes mutations, DNA repair genes, 
microsatellite instability, loss of heterozygosity have been reported in 
both esophageal and gastric cancers [45], genetic alterations in TP53 
tumor suppressor gene are fundamental events related in both early 
stage and advanced tumor. p53 mutation is a common event in human 
cancers which causes defects in apoptosis and makes cancer cells 
resistant to chemotherapeutic agents [46]. Alterations in p53 occur in 
gastric carcinoma and it increases in frequency during the course of 
gastric carcinoma developments [47]. In the presence of p53, capsaicin 
was a more potent pro-apoptotic agent than EU. However, silencing 
of p53 significantly apoptosis induced by capsaicin but not that by 
EU. Western blot analysis of pro-apoptotic markers revealed that as 
opposed to capsaicin, EU could induce caspase-8 and caspase-3 even 
Table 1: Phenylpropanoids, EU scaffold and its derivatives as cancer activity
phenylpropanoids, EU scaffold and its derivatives Activity/mechanism Animal/cell line References
EU (Eu) 1 MMP 16
Eu and canola oil Induced G1/S cell cycle HCT 116 23






Eu CDK Mamae xenograph 28
Eu derivatives Z, E isomer
EU with Z isomers compound 3 and 4, E isomers 5 and 6
Citotoxicity MDA-MB-231 29
Eu MMP 9 MCF7 30
Phenilpropanoide 7+5Fu Cell cycle HeLa 33
EU 1>ferulic 8>cinnamic 9>caffeic 10>chlorogenic 11>p-coumaric 
12>3,4-dimethoxycinnamic 13>2,4,5-trimethoxycinnamic acids 14




EU scaffold (hydrocarvicol) 15, 16, 17, and 18 Antiproliferative HeLa 36
EU and Eu Acetat 19 Citotoxicity B16 39
EU, IsoEu 20
O, O’-dimethyl-dehydrodi EU 21 O, O’-methylated 22 form  
(O, O’-dimethyl-dehydrodieugenol), 6,6’-dibromo-dehydrodieugenol 23 its 
enantiomeric form (S) 24
Citotoxicity 40
Eu E2F In vivo 17
Cell cycle UM1205Lu 41
Eu+honey L1210 in mouse 18
Eu ROS HL-60 43
Eu+capsaicin Caspase 9 dan 3, P53 48
Eu NfkB Wistar 49
Eu+methoxyestradiol G2/M Phase PC-3, Hep G2 52, 55
Eu and derivatives Citotoxicity DU-145, KB 53
5-allyl-3-nitrobenzene-1,2-diol 25 and 4-allyl-2-methoxy-5-nitrophenyl acetate 26 Citotoxicity TE-13 53
dihydro-eugenol 15, dehydrodiisoeugenol 27, isoeugenol, EU, and bis-eugenol 21 Citotoxicity HSG, HGF 56
ROS: Reactive oxygen species, EU: Eugenol, HGF: Human gingival fibroblasts
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in the absence of p53. EU was a better apoptotic agent than capsaicin 
because of its ability to induce the extrinsic pathway of apoptosis in 
a p53 independent. Loss of function of p53 tumor suppressor gene is 
implicated in defective apoptotic response of tumors to chemotherapy. 
Thus, agents which can induce apoptosis irrespective of the cellular p53 
status have immense scope for development as potential anticancer 
agents. Therefore, EU warrants further investigation for its potential 
use as anticancer agent against p53 defective or null tumors with poor 
prognosis [48].
Manikandan et al. [49] studied the treatment effect of EU on gastric 
cancer in Wistar rats caused by N-methyl-N’-nitryl-N-nitrosoguanidine 
by regarding apoptosis, cancer cell invasion, and angiogenesis as the 
main indices. They found that EU inhibits cell apoptosis, cancer cell 
invasion, and cancer angiogenesis by regulating the Bcl-2 protein 
family, apoptotic protease-activating factor-1 (Apaf-1), cytochrome C, 
and cysteine aspartic protease, and changes the activity of 
mesenchymal metalloprotease and the expression of MMP-2, MMP-9, 
vascular endothelial growth factor (VEGF), VEGF receptor 1, and 
tissue metalloprotease inhibitor (TIMP-2). MMP, VEGF, and TIMP are 
important observations indicating tumorigenesis. The same research 
by Manikandan et al. conducted effects of EU on NF-κB signaling 
in a rat model of gastric carcinogenesis induced by N-methyl-N’-
nitryl-N-nitrosoguanidine (MNNG) by analyzing the expression of 
nuclear factor-kappaB (NF-κB), the NF-κB target genes that promote 
(e.g., cyclin D1, cyclin B and PCNA) or inhibit (e.g., p53, p21, and 
Gadd45) cell proliferation and cell survival. MNNG-induced gastric 
tumors were characterized by NF-κB activation that correlated with 
upregulation of IKKβ, and phosphorylation and degradation of IκBα. 
Furthermore, upregulation of cyclins and PCNA with downregulation 
of p21, p53, and Gadd45 suggested that the proliferative advantage 
in gastric carcinomas is dependent on elevated constitutive NF-κB 
activity [50].
Anticancer activity of phenylpropanoids, EU scaffold and its 
derivatives against prostate
Prostate cancer is the second leading cause of cancer related deaths 
in men and will account for approximately 28,000 deaths every year 
with a dramatic increase in incidence with age [51]. The combination 
of 2-ME (methoxyestradiol) and EU (4-allyl-2-methoxyphenol) as an 
approach for enhancing anticancerous activities in prostate cancer 
cells. Combining 2-ME (2) with EU (i) inhibited growth of prostate 
cancer cells and induced apoptosis at lower concentrations than either 
single agent alone; (ii) analysis of the data using CI showed CI values of 
0.4 indicating strong synergistic interaction; (iii) increased population 
of cells G (2)/M phase by 4.5-fold (p=0.01); (iv) significantly reduced 
expression of antiapoptotic protein Bcl-2 and enhanced expression 
of proapoptotic protein Bax. Combination induced apoptosis was not 
affected in PC-3 cells that over-express or lack Bcl-2 but was associated 
with loss of mitochondrial membrane potential.
Since 2-ME was well tolerated in phase II try in patients with HRPC; 
and EU is consumed by humans in the form of spices, the combination 
of 2-ME with EU may offer a new clinically relevant treatment 
regimen. Combining these agents may allow ameliorating any adverse 
effects of either 2-ME or EU alone by reducing their individual 
concentrations should these two agents be developed for human use 
[52]. Curative effect of the combination of EU and 2-methoxyestradiol 
on non-androgen-dependent prostate cancer. They found that this 
combination could effectively inhibit the proliferation of prostate 
cancer cells and enhance the expression of apoptosis precursor 
protein to prevent prostate cancer [50]. Carrasco et al. [53] studied 
that EU and its derivatives against prostate cancer cells, namely DU-
145 (androgen-insensitive prostate cancer cells). This examined 
cancer cells, EU and its derivatives showed cell-growth inhibition 
activity. The study demonstrated that EU derivatives, such as 5-allyl-3-
nitrobenzene-1,2-diol 25 and 4-allyl-2-methoxy-5-nitrophenyl acetate 
26, were significantly (p<0.001) more active than EU, with IC50 values 
of 19.02×10−6 and 21.5×10−6 mol L−1.
Anticancer activity of phenylpropanoids, EU scaffold and its 
derivatives against other cancer
Furthermore, it has been demonstrated that EU with in vitro study 
shown that cytotoxic properties of the clove oil and EU, toward human 
fibroblasts and endothelial cells. Clove oil was found to be highly 
cytotoxic at concentrations as low as 0.03% (v/v) with up to 73% of 
this effect attributable to EU. beta-caryophyllene did not exhibit any 
cytotoxic activity, indicating that other cytotoxic components may also 
exist within the parent oil [54]. Volatile oils display cytotoxic action 
toward the human tumor cell lines PC-3 and Hep G2 50 [55]. A derivative 
of EU, dihydro- EU 27, has been shown to induce apoptosis of MCF [55]. 
Studies have demonstrated that EU provides protection from chemically 
induced skin cancer. Maximum cell death and apoptotic cell demise 
occurred in TE-13 cells within 24 hrs by clove oil at 300 μl/ml with 
80% cell death. In this way, Atsumi and collaborators [56] compared 
the cytotoxicity of dehydrodiiso EU 28, alpha-di-iso EU 29, iso EU, EU, 
and bis- EU 30 in a gland tumor cell line (HSG) and normal human 
gingival fibroblasts (HGF). These compounds against the salivary gland 
tumor cell line (HSG) and normal HGF were greatest in dehydrodiiso EU 
27 and alpha-di-isoeugenol 28, followed by isoeugenol, which showed 
greater activity than EU [54]. The EU analogs were examined by in vitro 
model of cancer using KB (oral squamous carcinoma cells) in KB cells 
of 18.11×10−6 and 21.26×10−6 mol L−1, respectively, suggesting that the 
presence of nitro and hydroxyl groups could be important in the activity 
of these compounds [55].
CONCLUSION
This review serves to provide a compiled that EU scaffold as 
chemoprevention utilizes appropriate pharmacological agents. 
The antiproliferative and molecular mechanism of EU with scaffold 
phenylpropanoids and its derivatives can induce apoptosis in various 
cancer cell lines and animal models. EU has developed as a promising 
candidate both in in vivo and in vitro studies.
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